New drug targets Hard-to-Treat cancers with PTEN loss
NCT ID NCT06360588
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 27 times
Summary
This study tests a drug called copanlisib in 22 adults with advanced solid tumors that have lost a protein called PTEN. The drug works by blocking certain enzymes that help cancer cells grow and survive. The main goal is to see if the tumors shrink or stop growing. This is a phase II trial, meaning the drug is already known to be safe and is now being tested for effectiveness in this specific group of patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.